Brought to you by 
Serono adds Newron's CNS compound safinamide to pipeline; safinamide portion terminated
28 Oct 2011
Executive Summary
Newron Pharmaceuticals SPA (ion channel modulators and neuroprotectors for CNS diseases) has licensed Serono SA exclusive global rights to develop, manufacture, and sell safinamide for Parkinson's, Alzheimer's, and other cognitive diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serono adds Newron's CNS compound safinamide to pipeline; safinamide portion terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice